ArticleJournal of translational medicine2026
FSTL1 promotes M2 polarization of macrophages via the DIP2A-Smad2/3 Axis in gastric cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollistatin-like protein 1 (FSTL1) is aberrantly overexpressed in gastric cancer (GC) and modulates immune cell infiltration in the tumor microenvironment. However, the molecular mechanism underlying its regulation of macrophage polarization remains incompletely defined.
methodsIn this study, we analyzed the expression of FSTL1 and its correlations with clinical prognosis and M2 macrophage infiltration using data from The Cancer Genome Atlas (TCGA) database and clinical GC tissue microarrays. In vitro experiments were conducted to validate the effect of FSTL1 on M2 polarization, and a mouse subcutaneous syngraft tumor model was established to substantiate its in vivo role. Combined analyses involving transcriptome sequencing, single-cell sequencing, and coimmunoprecipitation were performed to identify the key receptors and signaling pathways involved in FSTL1-mediated regulation.
resultsThe expression of FSTL1 was significantly upregulated in GC tissues, and its high expression was positively correlated with advanced clinical stage, unfavorable clinical outcomes, and increased M2 macrophage infiltration. In vitro, GC cell-derived FSTL1 markedly increased M2 polarization in both THP-1-derived M0 macrophages and monocyte-derived macrophages. This effect was significantly attenuated by FSTL1 knockdown in GC cells and was restored in a dose-dependent manner by supplementation with exogenous recombinant FSTL1. In vivo, Fstl1 knockdown suppressed syngeneic tumor growth, reduced the proportions of M2 macrophages and regulatory T cells, and increased the proportion of Cd8a⁺ T cells in tumor tissues. Mechanistically, FSTL1 was found to bind to its functional receptor DIP2A to induce Smad2/3 phosphorylation, thereby promoting macrophage M2 polarization, and blockade of either DIP2A or the TGF-β signaling pathway attenuated this effect. Notably, we identified a reciprocal positive feedback loop between GC cells and macrophages: tumor-derived FSTL1 activated the TGF-β/Smad2/3 pathway in macrophages to promote M2 polarization, and polarized M2 macrophages in turn secreted large amounts of TGF-β to further upregulate FSTL1 expression in GC cells. This positive feedback loop sustained M2 macrophage enrichment in the GC microenvironment, which reinforced the immunosuppressive landscape and contributed to the progression of tumors to malignancy.
conclusionsThese findings indicate that FSTL1 represents a promising immunomodulatory target and highlight its potential as a therapeutic target to reprogram the immunosuppressive microenvironment and improve the efficacy of GC immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.